Bristol-Myers Squibb
BMS enters gene therapy development deal
April 7, 2015Research and Development BMS, Bristol-Myers Squibb, R&D, cardiovascular disease, cvd, heart disease, heart failure, uniQure
Bristol-Myers Squibb (BMS) has signed a multi-million dollar agreement with Amsterdam-based gene therapy firm uniQure to boost research into new …
Funding boost for UK drugs manufacturing
March 30, 2015Manufacturing and Production, Sales and Marketing ABPI, AstraZeneca, BIA, Bristol-Myers Squibb, Britest, Cambridge, Cambridge Crystallographic Data Centre, GlaxoSmithKline, Perceptive Engineering, Pfizer, Process Systems Enterprise, UCB, University of Leeds, amsci, mmip, stfc
The UK government is funding new manufacturing partnerships that will improve design processes and supply chain initiatives to lift the …
BMS backs rheumatoid arthritis prevention trial
March 27, 2015Sales and Marketing BMS, Bristol-Myers Squibb, Orencia, RA, abatacept, rheumatoid arthritis
Bristol-Myers Squibb is funding a £3 million trial of Orencia as a preventative treatment for rheumatoid arthritis. The study will …
BMS in $1.5 billion immuno-oncology expansion
February 24, 2015Research and Development, Sales and Marketing BMS, Bristol-Myers Squibb, Rigel, flexus, immuno-oncology
Bristol-Myers Squibb has confirmed two major deals to enhance the company’s standing in the immuno-oncology field. The first agreement sees …
BMS wins FDA approval for HIV pill
January 30, 2015Sales and Marketing BMS, Bristol-Myers Squibb, FDA, Gilead, Reyataz, atazanavir, cobicistat), evotaz, tybost
Bristol-Myers Squibb has earned FDA approval for its HIV combination treatment Evotaz. The US drugs regulator gave BMS the go-ahead …
BMS names operating officer as new chief executive
January 21, 2015Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing BMS, Bristol-Myers Squibb, Giovanni Caforio, Lamberto Andreotti, Yervoy, opdivo
Bristol-Myers Squibb’s chief operating officer Giovanni Caforio will be stepping in to Lamberto Andreotti’s shoes as chief executive from May …
BMS lung cancer drug scores in Phase II
October 31, 2014Sales and Marketing BMS, Bristol-Myers Squibb, Cancer, FDA, NSCLC, bristol myers-squibb, odivo
Bristol-Myers Squibb is still in the hunt to gain significant market share in the PD-1 therapeutic vaccine race after releasing …
BMS therapeutic cancer vaccine given swift FDA appraisal
September 29, 2014Sales and Marketing BMS, Bristol-Myers Squibb, Cancer, FDA, Vaccine, bristol myers-squibb, keytruda, melanoma, opdivo
Bristol-Myers Squibb has been granted a speedy review for its new cancer immunotherapy drug Opdivo by the FDA for patients …
NICE and market access: time for reform?
August 26, 2014Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing ABPI, Bristol-Myers Squibb, NICE, Yervoy, reform
Earlier in the year, at the ABPI’s annual conference, the UK pharma lobby group released a new report suggesting that …
Bristol-Myers Squibb hires new general manager




June 11, 2014Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Amadou Diarra, BMS, Bristol-Myers Squibb, Johanna Mercier
Johanna Mercier has been appointed as Bristol-Myers Squibb’s general manager for the UK and Ireland. The appointment of Mercier who …
Pharma creates non-profit R&D organisation
September 21, 2012Research and Development, Sales and Marketing Abbott, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Eli Lilly and Co, GlaxoSmithKline, Johnson & Johnson, Pfizer, R&D, Roche Genentech, Sanofi, TransCelerate BioPharma, biopharma
Ten biopharma companies have formed TransCelerate BioPharma Inc, a not-for-profit organisation using money and personnel from each firm, with a …
BMS skin cancer vaccine hits phase III target
March 23, 2011Research and Development BMS, Bristol-Myers Squibb, advanced inoperable skin cancer, advanced melanoma, cancer drugs, cancer vaccine, ipilimumab
Bristol Myers Squibb’s cancer vaccine ipilimumab has increased overall survival in advanced melanoma patients. The therapy was being tested as …
Pharma manufacturing news in brief
March 8, 2011Manufacturing and Production Bristol-Myers Squibb, CSM GlobalPharma, Carbogen Amcis, Quotient Clinical, SCM Pharma, WuXi PharmaTech
Facility updates from Bristol-Myers Squibb, WuXi PharmaTech, Quotient Clinical, CSM GlobalPharma and SCM Pharma, plus a reorganisation of Carbogen Amcis’ …
Onglyza expands European licence
March 4, 2011Sales and Marketing AZ, AstraZeneca, BMS, Bristol-Myers Squibb, Onglyza, diabetes, renal impairment, saxagliptin, type II diabetes
European regulators have approved a licence extension for diabetes treatment Onglyza, making it the first drug in its class that …
Working Life: BMS UK’s market access director Patrick Hopkinson
February 24, 2011Business Services, Medical Communications, Sales and Marketing BMS, Bristol-Myers Squibb, Patrick Hopkinson, Working Life, recruitment
Patrick Hopkinson, director of market access and external affairs at Bristol-Myers Squibb UK, talks to Pharmafocus about how he got …
Latest content
